Hide and Seek… Can We Eradicate HIV by Treatment Intensification?
Authors:
- Julian Schulze Zur WieschJWJulian Schulze Zur Wiesch
- Jan van LunzenJLJan van Lunzen
Open Access
- 1 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 203 (7) , 894-897
Abstract
(See the article by Hatano et al., on pages 960–68 .)Keywords
This publication has 26 references indexed in Scilit:
- A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell ResponseThe Journal of Infectious Diseases, 2011
- Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradicationAIDS, 2010
- Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV InfectionJournal of Virology, 2010
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapyAIDS, 2010
- Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV‐1 InfectionThe Journal of Infectious Diseases, 2010
- Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral TherapyClinical Infectious Diseases, 2010
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyProceedings of the National Academy of Sciences, 2009
- Emerging Concepts in the Immunopathogenesis of AIDSAnnual Review of Medicine, 2009
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006